Omapatrilat: Clinical pharmacology

Drugs of Today

Volumn 36, Issue 12, 2000, Pages 817-828

  Cases, A ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OMAPATRILAT; PROTEINASE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ENZYME INHIBITION; HEART DISEASE; HOSPITALIZATION; HUMAN; HYPERTENSION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE;

EID: 0034480080     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Omapatrilat
2. Vasopeptidase inhibition: A new concept in blood pressure management
3. Steady-state pharmacokinetics of omapatrilat in healthy subjects
4. Omapatrilat does not affect the steady state of warfarin
5. Coadministration of omapatrilat does not alter furosemide induced diuresis
6. Effects of BMS-186716, a new dual metalloprotease inhibitor, on pharmacodynamic markers of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) activity in healthy men
7. Pharmacodynamic effects of multiple doses of omapatrilat in healthy subjects
8. Supine mean arterial blood pressure (MAP) lowering and oral tolerance of BMS-186716, a new dual metalloprotease inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP), in healthy male subjects
9. Omapatrilat is not a diuretic: Single- and multiple-dose analysis of the urinary excretion of sodium
10. The safety and 24-hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat: A pilot study
11. Efficacy and safety of omapatrilat, a vasopeptidade inhibitor
12. Omapatrilat, a vasopeptidase inhibitor is an effective antihypertensive agent in mild to moderate hypertension
13. Double-blind withdrawal of omapatrilat after long-term stable administration demonstrates persistence of antihypertensive efficacy
14. Hypertensive subjects uncontrolled with hydrochlorothiazide monotherapy are responsive to vasopeptidase inhibition with omapatrilat
15. Antihypertensive efficacy of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril
16. Omapatrilat versus losartan in hypertensive patients with left ventricular hypertrophy
17. Randomized double-blind comparison of omapatrilat with amlodipine in mild-to-moderate hypertension
18. Omapatrilat compared with lisinopril in treatment of hypertension as assessed by ambulatory blood pressure monitoring
19. Vasopeptidase inhibition and angioedema
20. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans
21. Neurohormonal effects of vasopeptidase inhibition with omapatrilat in hypertension
22. Vasopeptidase inhibition, omapatrilat and angiotensin-(1-7)
23. Omapatrilat increases key vascular/renal markers regardless of renal function
24. The effect of vasopeptidase inhibition by omapatrilat in salt-sensitive hypertensives
25. Renal characteristics of omapatrilat in salt-sensitive hypertensive patients
26. Efficacy and safety of omapatrilat in subjects with isolated systolic hypertension
27. Omapatrilat in elderly hypertensive patients: A placebo-controlled trial
28. Effects of renal function on pharmacokinetics of omapatrilat
29. The safety and efficacy of omapatrilat in patients with hypertension and renal insufficiency
30. Omapatrilat, a novel cardiovascular agent improves hemodynamics in patients with heart failure
31. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
32. Beneficial effects of vasopeptidase inhibition on mortality and morbidity in heart failure: Evidence from the Omapatrilat Heart Failure Program
33. The vasopeptidase inhibitor, omapatrilat, has a favorable, pressure-independent effect on conduit vessel stiffness in patients with congestive heart failure
34. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
35. Omapatrilat in persons with enhanced risk of atherosclerotic events: The OPERA trial